Pre‐treatment carbohydrate antigen 19‐9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1477-2574|17|10|942-952

ISSN： 1365-182x

Source： HPB, Vol.17, Iss.10, 2015-10, pp. : 942-952

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer

By  

Oncology, Vol. 70, Iss. 4, 2006-10 ,pp. : 255-264

Karger

Access to resources Recommend Favorite

Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 19, Iss. 6, 2012-11 ,pp. : 717-722

John Wiley & Sons Inc

Access to resources Recommend Favorite

Erratum to: Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 19, Iss. 6, 2012-11 ,pp. : 723-723

John Wiley & Sons Inc

Access to resources Recommend Favorite

CA 19-9 Response as an Early Indicator of the Effectiveness of Gemcitabine in Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 75, Iss. 1-2, 2008-09 ,pp. : 120-126

Karger

Access to resources Recommend Favorite

Limited Value of CA 19-9 in Predicting Early Treatment Failure in Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 140-146

Karger

Access to resources Recommend Favorite